September 22, 2024

Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

This study aimed to investigate exposure-response (ER) relationships in efficacy and safety for mirvetuximab soravtansine (MIRV) which is a first-in-class antibody-drug conjugate approved for the treatment of folate receptor-α-positive platinum-resistant ovarian cancer.

Preguntar a la IA

Me gusta

Guardar

Cite This Study

Tu et al. (Sun,) studied this question.

synapsesocial.com/papers/68e57aefb6db64358751a94a https://doi.org/https://doi.org/10.1111/bcp.16250

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The influence of birth cohort and calendar period on global trends in ovarian cancer incidence2019 · 133 citations
2Platinum Resistance in Ovarian Cancer: Role of DNA Repair2019 · 303 citations
3Targeting folate receptor alpha for cancer treatment2016 · 453 citations
4Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study2003 · 2,056 citations
5Ovarian cancer statistics, 20182018 · 3,723 citations

Preguntar a la IA

Me gusta

Guardar